Samantha M. Sarrett
Samantha M. Sarrett has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Devra J. Olson
Pfizer, Inc., Bothell, Washington
23 shared publications - Andrea R. Lim
Pfizer, Inc, Bothell, Washington
22 shared publications - Bryan Grogan
Pfizer, Inc., Bothell, Washington
22 shared publications - Christopher M. Carosino
Pfizer, Inc., Bothell, Washington
22 shared publications - Cristina L. Abrahams
Sutro BioPharma, South San Francisco, California
22 shared publications - Daniel Diolaiti
Memorial Sloan Kettering Cancer Center 9 Bothell
22 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
PF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Open AccessPF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
CD25 expression in the microenvironment of solid tumor indications.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
CD25 expression in the microenvironment of solid tumor indications.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S3 shows the identification of affinity-detuned Clone123-YH98A.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S3 shows the identification of affinity-detuned Clone123-YH98A.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S4 shows that PF-08046032 maintains specific binding and internalization to CD25+ cells.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S4 shows that PF-08046032 maintains specific binding and internalization to CD25+ cells.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S12 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S12 shows the PK/PD analysis of PF-08046032 in cynomolgus monkeys.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S12 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S12 shows the PK/PD analysis of PF-08046032 in cynomolgus monkeys.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Percentage of Tumor Growth Inhibition (%TGI) for lymphoma xenografts.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Percentage of Tumor Growth Inhibition (%TGI) for lymphoma xenografts.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
X50 values for PF-08046032 across a panel of CD25-expressing cell lines.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
X50 values for PF-08046032 across a panel of CD25-expressing cell lines.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
%TGI for syngeneic mouse models.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
%TGI for syngeneic mouse models.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S8 shows the effect of conjugating Clone123 with other payloads on Tregs and T cells.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S8 shows the effect of conjugating Clone123 with other payloads on Tregs and T cells.